2m 2m 2m 2m 2m 2m 2m
- $2.3MMarket Cap
- -93.52%1-Year Change
- BiotechnologyIndustry
LUNAI BIOWORKS (LNAI)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
Law firms Dickinson Wright and Fox Rothschild filed a federal lawsuit on behalf of Lunai Bioworks alleging securities fraud and market manipulation by unnamed naked short sellers. The complaint details systematic failures to deliver shares reaching 234.6 times the maximum baseline rate, with trading volumes exceeding Lunai's total outstanding shares by multiples. The lawsuit seeks compensatory damages and injunctive relief to halt the manipulative trading.
05/12/2026, 12:12 AM • GlobeNewswire
U.S. stock futures were mixed on Friday following Thursday's decline as President Trump extended the Israel-Lebanon ceasefire by three weeks. The Dow Jones fell 0.20%, S&P 500 declined 0.028%, while Nasdaq rose 0.56%. Key stocks in focus include Intel (beat earnings expectations), SAP (beat earnings), Lunai Bioworks (announced $20M transaction), Procter & Gamble (earnings expected), and FreeCast (signed DIRECTV distribution deal). Oil prices rose to $97.15/barrel, and the Fed is expected to hold rates unchanged in April.
04/24/2026, 8:48 AM • Benzinga
U.S. stock futures were mixed on Friday following Thursday's decline as President Trump extended the Israel-Lebanon ceasefire by three weeks. The Dow Jones fell 0.20% while the Nasdaq rose 0.56%. Key stocks in focus include Intel (beat earnings expectations), SAP (beat earnings), Lunai Bioworks (announced $20M transaction), Procter & Gamble (earnings expected), and FreeCast (signed DIRECTV distribution deal). Oil prices rose to $97.15/barrel, and the Fed is expected to hold rates unchanged in April.
04/24/2026, 5:31 AM • Benzinga
Lunai Bioworks announced that its subsidiary BioSymetrics has secured its first revenue-generating defense collaboration to develop an AI-enabled platform for chemical threat assessment. The multi-year commercial engagement combines zebrafish-based phenotypic screening with AI-driven mechanism-of-action prediction to detect and characterize chemical threats, with additional engagements under discussion.
04/07/2026, 9:05 AM • Benzinga
Law firm Kahn Swick & Foti is investigating the proposed merger between Predictive Oncology and Renovaro, questioning whether the transaction adequately values the company.
08/19/2025, 9:44 PM • GlobeNewswire
AI Just Got a Green Light from the White House--Here's What That Means for Healthcare Stocks
The White House is encouraging AI adoption in healthcare through regulatory sandboxes, with several tech and biotech companies advancing AI-powered healthcare solutions focused on diagnostics, drug development, and workflow optimization.
07/29/2025, 3:01 PM • Benzinga
Peers
Statistics
MoreInformation as of 10/21/2026
Company Profile
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, provides medicine, diagnostics, and biodefense products the United States, Canada, and the Netherlands. It operates through two segments, RENB and BioSymetrics. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer. It also develops BioSymetrics platform, for multi-omics integration for target identification and validation; clinical trial optimization, including patient stratification and response monitoring; and screening of gene and small molecule effects for the purpose of identifying novel drug targets and therapeutics. The company was formerly known as Renovaro Inc. and changed its name to Lunai Bioworks Inc. in August 2025. Lunai Bioworks Inc. is based in Sacramento, California.
Key Executives
- David H. Weinstein
- Nathen Fuentes
Current Ownership Distribution
- Other3.7M (80.80%)
- Mutual Funds870,702 (19.20%)
- Institutions0 (0.00%)
- Insiders0 (0.00%)